Experimental studies in the colon of rodents Morphological and Functional Study of the mice and rat colon after exposure to chemotherapeutics or psychosolcial stress and treatment with prebiotics or otilonium bromide

Study1: Background. Cisplatin, an antimitotic agent, is known to cause both acute and chronic gastrointestinal side effects. Acute effects primarily consist in a mucositis, while chronic effects are due to neuropathy. Additionally, cisplatin has antibiotic properties that disrupt the microbiota, leading to dysbiosis, which intensifies inflammation and exacerbates local tissue damage. A strategy to protect the microbiota could potentially reduce the toxicity associated with chemotherapy. Furthermore, as a healthy microbiota may enhance the effectiveness of chemotherapeutic agents, prebiotics could also improve cisplatin's therapeutic outcomes. Aim and methodology. In this study, we explored whether chronic cisplatin administration leads to morphological and functional changes in the proximal colon of mice, and whether a prebiotic-enriched diet could provide protective benefits. Results. Our findings revealed that cisplatin administration resulted in poor weight gain, increased kaolin consumption, and reduced stool production and mucus secretion. Prebiotics effectively mitigated the increase in kaolin intake and the alterations in stool production and mucus secretion, although they did not impact weight gain. Moreover, cisplatin reduced the amplitude of spontaneous colonic muscle contractions and decreased Connexin (Cx)43 expression in ICC, changes that were partially prevented by prebiotic supplementation. Conclusions. our study demonstrates that daily prebiotic administration, likely through the protection of the microbiota, prevents most cisplatin-induced colonic changes. Study 2: Background. Cisplatin, an antimitotic agent, is known to cause both acute and chronic gastrointestinal side effects. Acute effects primarily consist in a mucositis, while chronic effects are due to neuropathy. Additionally, cisplatin has antibiotic properties that disrupt the microbiota, leading to dysbiosis, which intensifies inflammation and exacerbates local tissue damage. A strategy to protect the microbiota could potentially reduce the toxicity associated with chemotherapy. Furthermore, as a healthy microbiota may enhance the effectiveness of chemotherapeutic agents, prebiotics could also improve cisplatin's therapeutic outcomes. Aim and methodology. In this study, we explored whether chronic cisplatin administration leads to morphological and functional changes in the proximal colon of mice, and whether a prebiotic-enriched diet could provide protective benefits. Results. Our findings revealed that cisplatin administration resulted in poor weight gain, increased kaolin consumption, and reduced stool production and mucus secretion. Prebiotics effectively mitigated the increase in kaolin intake and the alterations in stool production and mucus secretion, although they did not impact weight gain. Moreover, cisplatin reduced the amplitude of spontaneous colonic muscle contractions and decreased Connexin (Cx)43 expression in ICC, changes that were partially prevented by prebiotic supplementation. Conclusions. our study demonstrates that daily prebiotic administration, likely through the protection of the microbiota, prevents most cisplatin-induced colonic changes.